Aarti Pharmalabs Ltd announced stellar Q3 FY26 results: consolidated net profit of ₹479.6 million and revenue from operations at ₹4.32 billion for the December quarter. The board declared a ₹1.50 per share interim dividend, reflecting strong financial health amid pharma sector resilience and strategic growth.
Aarti Pharmalabs Ltd reported consolidated net profit of 479.6 million rupees for the December quarter FY26, alongside revenue from operations at 4.32 billion rupees. The board declared an interim dividend of 1.50 rupees per equity share, signaling shareholder confidence amid robust financials. Key highlights include solid total income growth and strategic provisions for regulatory changes.
Key Financial Metrics
-
Standalone total income reached 424.88 crore rupees for Q3 FY26, with profit before tax at 58.58 crore rupees and net profit at 43.84 crore rupees, yielding basic EPS of 4.84 rupees.
-
Consolidated figures showed total income of 431.90 crore rupees, profit before tax at 62.87 crore rupees, and net profit attributable to owners at 47.96 crore rupees, with EPS at 5.29 rupees.
Strategic Highlights
The board approved an interim dividend of 1.50 rupees per share (30% on 5-rupee face value), with record date February 16, 2026. An exceptional provision of 2.79 crore rupees addressed new labor codes impact. Revenue of 49.35 crore rupees from goods in transit excluded, to reflect in Q4 FY26.
Outlook Insights
These Q3 FY26 results underscore Aarti Pharmalabs' resilience in pharmaceutical manufacturing, with AARP.NS focusing on API intermediates and expansions. Investors track YoY trends in Aarti Pharmalabs earnings, margins, and dividend policy for pharma sector updates.
Sources: Reuters (RTRS), BSE via InvestyWise